# A Phase I/II Study of Diffuse Large B-cell Lymphoma

> **NCT04856137** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 74 (estimated)

## Conditions studied

- Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Rituximab Paclitaxel Ruxolitinib

## Key facts

- **NCT ID:** NCT04856137
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-05-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2021-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856137, "A Phase I/II Study of Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04856137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*